Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease…
Apptly Announces $1,000,000 Non-Brokered Private Placement
SATO Technologies Corp. Announces Loan Settlement Eliminating All of Its Senior Secured Debt and C$1.5 Million Private Placement
Theralase(R) Closes C$3.6 Million Brokered Financing